Amy Holroyd
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.
Journal: The Lancet. Oncology
Published: December 03, 2025
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial.
Journal: British journal of haematology
Published: October 02, 2025
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Journal: Blood
Published: September 06, 2022
A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study.
Journal: Neuro-oncology
Published: May 19, 2019
Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia.
Journal: Nature communications
Published: January 22, 2019
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.
Journal: Nature communications
Published: January 12, 2019
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility.
Journal: Nature communications
Published: January 10, 2019
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Journal: Nature communications
Published: October 31, 2018
Genome-wide association analysis identifies a meningioma risk locus at 11p15.5.
Journal: Neuro-oncology
Published: May 16, 2018
Last Updated: 09/26/2026